JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A8307 Crenolanib (CP-868596)
1 Citation

Target: FLT3|PDGFR

Summary: PDGFR-β inhibitor,potent and selective

≥22.2 mg/mL
A8476 MK-2461

Target: FLT3|PDGFR|MET|Ron

Summary: C-Met (WT/mutants) inhibitor

≥24.8 mg/mL
B1404 DCC-2036 (Rebastinib)

Target: FLT3|Bcr-Abl|Tie-2|KDR

Summary: Bcr-Abl inhibitor

≥27.7 mg/mL
A8889 G-749

Target: Aurora Kinases|FLT3|c-RET

Summary: FLT3 inhibitor

≥26.05 mg/mL
B5832 Altiratinib
1 Citation

Target: FLT3|VEGFR|Trk Receptors|c-MET|Tie-2

Summary: c-MET/TIE-2/VEGFR inhibitor

≥21.55 mg/mL
B5854 Pexidartinib (PLX3397)
3 Citation

Target: FLT3|c-Kit|CSF1R

Summary: CSF-1R inhibitor

insoluble in EtOH; insoluble in H2O; ≥20.9 mg/mL
B5953 Dovitinib (TKI258) Lactate

Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).

insoluble in EtOH; ≥10.62 mg/mL